Kuiken schreef op 6 september 2023 11:18:ik herhaal deze post nog maar een keer. VIVO heeft nu iemand aan het roer die weet hoe je een medicijn in Europa ,US en Japan naar de mark brengt!!
Staat al langer op de website natuurlijk, maar nog een keer wat VIVO meldt over hun nieuwe CEO,
Frank Weber has been our Chief Executive Officer since August 2023 and has served as our Chief Medical Officer since 2010. He has 30 years of experience in the pharmaceutical and life science industry.
Frank Weber supported InterMune (now Genentech/Roche), in particular, its launch
of Esbriet in Europe, as Global Clinical Advisor. Prior to this, he served as Chief Medical Officer at Merck KGaA in Germany and Switzerland, where he contributed to several marketing authorizations and market access agreements in the EU, U.S. and Japan and also spearheaded personalized medicine, biomarker and companion diagnostics.
During his career, Frank Weber has also been involved in several M&A transactions as well as licensing deals
. His past roles include management positions in medical affairs and clinical development at American Cyanamid (Lederle), USA and at Synthelabo (now Sanofi), France. Frank Weber is also a board member at Zambon Biotech SA.
Frank Weber started his industry career after 10 years in academic clinical research and patient care in the areas of cancer, immunology, infectiology and maxillo-facial surgery. He is a licensed physician and received his MD in Cancer Immunology from the Medical University Cologne, Germany.
*Assuming CEO responsibilities effective August 14, 2023; proposed appointment to Vivoryon’s Board as executive director at Extraordinary General Meeting on September 15, 2023.